Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
MK-4827 tosylate
217
CHF
CHF 217.00
In stock
CDX-M0565-M01010 mgCHF 217.00
CDX-M0565-M05050 mgCHF 474.00
| Product Details | |
|---|---|
| Synonyms | Niraparib tosylate; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 4 methylbenzenesulfonate |
| Product Type | Chemical |
| Properties | |
| Formula | C19H20N4O . C7H8O3S |
| MW | 492.6 |
| CAS | 1038915-73-9 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥99% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO or DMF (both 20mg/ml). Sparingly soluble in ethanol (1mg/ml) or water (<1mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | LCPFHXWLJMNKNC-PFEQFJNWSA-N |
| Smiles | NC(C1=CC=CC2=CN(C3=CC=C([C@H]4C[NH2+]CCC4)C=C3)N=C21)=O.CC5=CC=C(S(=O)([O-])=O)C=C5 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
MK-4827 is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) and PARP2 (IC50s=3.8 and 2.1nM, respectively). It inhibits the proliferation of cancer cells carrying the breast cancer mutations BRCA1 and BRCA2 in vitro and has efficacy alone against a xenograft of BRCA1-deficient cancer in mice. MK-4827 sensitizes human lung and breast cancer xenografts to radiation in mice.3 Formulations containing MK-4827 are effective against ovarian cancer.
Product References
(1) P. Jones, et al.; J. Med. Chem. 52, 7170 (2009) | (2) Y. Yuan, et al.; J. Hematol. Oncol. 4, 1 (2011) | (3) L. Wang, et al.; Invest. New Drugs 30, 2113 (2012) | (4) M.R. Mirza, et al.; N. Engl. J. Med. 375, 2154 (2016) | (5) K.N. Moore, et al.; Gynecol. Oncol. 149, 214 (2018) (Review)